As part of an ongoing investigation into the 340B drug discount program, House Energy & Commerce Chair Greg Walden (R-OR) and oversight subcommittee Chair Tim Murphy (R-PA) are asking 340B providers to detail the savings they are receiving from the program, who the drugs go to and how savings are used. Earlier this year, Walden, Murphy and health subcommittee Chair Michael Burgess (R-TX) -- who did not sign the most recent letter -- told the Health Resources and Services Administration...